Chemical Structure (Asmanex 01)
Asmanex Inhalant
Product Images NDC 78206-114
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Asmanex (NDC 78206-114). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Organon Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure (Asmanex 02)
Mean Change in FEV:(L) data for a 12-Week trial comparing ASMANEX TWISTHALER vs. placebo in patients who were previously maintained on inhaled beta;-agonists. The graph shows the change in FEV1 over time, with statistically significant improvement seen in the ASMANEX TWISTHALER group compared to the placebo group.*
Figure (Asmanex 03)
This is a graph showing the results of a 12-week trial in patients who were previously using inhaled corticosteroids. The graph shows different treatment groups including Asmanex Twisthaler at 220mcg once-daily, Asmanex Twisthaler at 440mcg once-daily in the evening, Asmanex Twisthaler at 220mcg twice-daily, and a placebo group. The vertical axis shows the mean change from baseline in morning peak expiratory flow (PEF) in liters per minute. The horizontal axis shows the duration of the trial in weeks. The graph shows that Asmanex Twisthaler at 220mcg once-daily, Asmanex Twisthaler at 440mcg once-daily in the evening, and Asmanex Twisthaler at 220mcg twice-daily had a significant positive impact on morning peak expiratory flow compared to the placebo group.*
Figure (Asmanex 04)
This is a graph showing the results of a 12-week trial in children aged 4 to 11 years, using a medication called Asnanex at a dosage of 110 mcg. The graph charts the change in predicted FEV (a measure of lung function) over time from baseline, compared to a placebo. The mean change in % predicted FEV is shown. Endpoint refers to the last available data for each subject.*
Figure (Asmanex 05)
This text is providing two figures of the TWISTHALER medicine inhaler in different positions.*
Figure (Asmanex 06)
This text provides instructions on how to open and use an inhaler. It instructs the reader to hold the inhaler upright and twist the cap in a counterclockwise direction to open it. Additionally, there is an image of the inhaler, which shows the cap and a ventilation hole. It is presumed that this information is part of a larger document or set of instructions for using the inhaler.*
Figure (Asmanex 07)
The text appears to be a warning or instruction related to a medical inhalation device. It notes the presence of ventilation holes and advises not to cover them while inhaling the dose. It also references a figure labeled as "Figure D: Inhalation".*
Figure (Asmanex 08)
This text appears to be instructions for closing a TWISTHALER device. The user is informed to ensure that the indented arrow lines up with the dose counter before replacing the cap and twisting it clockwise until a "click" is heard. There is also an accompanying figure, labeled "Figure E," which shows the proper way to close the TWISTHALER.*
Principal Display Panel (220 mcg)
This is the description of a medication called Asmanex Twisthaler that is only available via prescription for oral inhalation. It contains 220 milligrams of mometasone furcate nhalation powder per actuation and is recommended for more than two inhalations per day. The Twisthaler is meant to be discarded after 45 days of opening the package or when the dose counter reads 00. The inhaler comes with instructions for use, and patients should detach and dispose of this information with the inhaler. It is advised to store the Twisthaler in a cool place with controlled room temperature. For more information, the website www.asmanex.com can be visited, and the medication is manufactured by Organon & Co.*
Principal Display Panel (110 mcg)
This is a product description for Asmanex Twisthaler, a medication for oral inhalation. It contains mometasone furoate inhalation powder, with 110 meg per actuation, and comes with 30 metered doses. Each metered dose contains 110 meg of mometasone furoate with lactose, delivering 100 mcg mometasone furoate. The inhaler should be discarded 45 days after opening the pouch or when the dose counter reads "00", whichever comes first. The product should be stored in a dry place at 25°C (77°F), with excursions permitted to 15.30°C (59-86°F) [see USP Controlled Room Temperature]. The package includes patient instructions for use and disposal. For more information about Asmanex, customers can visit www.asmanex.com. The manufacturer is Organon LLC, a subsidiary of Organon & Co., located in New Jersey, USA.*
Figure (Asmanex 11)
The text describes a feature on a device called TWISTHALER, which produces a “click” sound to inform the user that the cap is fully closed. The closure of the cap is important to ensure that the medicine is properly loaded, and the device is ready to administer the next dose. The text also mentions figure F as a closed TWISTHALER.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
